Positive effect of metformin treatment in colorectal cancer patients with type 2 diabetes: national cohort study

We aimed to estimate colorectal cancer risk in patients with type 2 diabetes mellitus (T2DM) using metformin. Patients with colorectal cancer and diabetes from 2000 to 2012 were identified form Lithuanian Cancer Registry and the National Health Insurance Fund database. Standardized incidence ratios (SIRs) for colorectal cancers as a ratio of observed number of cancer cases in people with diabetes to the expected number of cancer cases in the underlying general population was calculated. We analysed 111 109 patients with diabetes. Overall, 1213 colorectal cancers were observed versus 954.91 expected within a period of observation entailing an SIR of 1.27 [95% confidence interval (CI): 1.20–1.34]. Significantly higher risk of colorectal cancer was found both in male and female patients with diabetes in all age groups. Higher risk was found for both colon and rectum cancers 1.36 (95% CI: 1.27–1.46) and 1.11 (95% CI: 1.01–1.22), respectively. There were no differences in risk over time since initial diabetes diagnosis. Never-users of metformin had twice higher risk of colorectal cancer compared to general population (SIR: 2.14, 95% CI: 1.95–2.35). Among metformin users, risk was lover (SIR: 1.47, 95% CI: 1.36–1.58) and colorectal cancer risk decreased with increasing cumulative dose of metformin (P 
Source: European Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Research paper: Colorectal cancer Source Type: research